Shares Magazine
3.66p+0.21 (+6.23%)24 Sep 2024, 13:23
Jump to:
Shield Therapeutics PLC Fundamentals
| Company Name | Shield Therapeutics PLC | Last Updated | 2024-09-24 |
|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Sector | Healthcare |
| Shares in Issue | 782.056 m | Market Cap | £28.66 m |
| PE Ratio | 32.15 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -$0.05 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.4271 | Debt Equity Ratio | 36.3752 |
| Asset Equity Ratio | 86.4344 | Cash Equity Ratio | 14.9704 |
| Quick Ratio | 0.8856 | Current Ratio | 1.05 |
| Price To Book Value | 66.2252 | ROCE | 0 |
Shield Therapeutics PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Shield Therapeutics PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | $673,000.00 | $238,000.00 | $410,000.00 |
| Intangible Assets | $16.86 m | $14.21 m | $36.22 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | $17.54 m | $14.45 m | $36.63 m |
| Stocks | $3.20 m | $1.76 m | $2.21 m |
| Debtors | $10.60 m | $3.99 m | $3.95 m |
| Cash & Equivalents | $13.95 m | $3.40 m | $16.34 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | $48.80 m | $26.62 m | $59.91 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | $13.73 m | $12.83 m | $4.56 m |
| Creditors after 1 year | $20.03 m | $7.25 m | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | $33.77 m | $20.07 m | $4.56 m |
| Net assets | $15.03 m | $6.54 m | $55.35 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | $15.01 m | $5.37 m | $4.57 m |
| Share Premium | $198.76 m | $169.48 m | $167.42 m |
| Profit / Loss | -$32.38 m | -$49.34 m | -$26.87 m |
| Other Equity | $15.03 m | $6.54 m | $55.35 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | $15.03 m | $6.54 m | $55.35 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | $0.57 | $0.53 | 0 |
| Debt-to-Equity | $1.33 | $1.11 | 0 |
| Assets / Equity | 86.4344 | 86.4344 | 86.4344 |
| Cash / Equity | 14.9704 | 14.9704 | 14.9704 |
| EPS | -$0.05 | -$0.15 | -$0.13 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -$37.13 m | -$22.59 m | -$24.65 m |
| Cashflow before financing | $12.53 m | -$14.06 m | $12.75 m |
| Increase in Cash | $10.10 m | -$11.81 m | $9.99 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | $13.09 m | $5.50 m | $2.05 m |
| Cost of sales | $9.06 m | $3.04 m | $1.32 m |
| Gross Profit | $4.03 m | $2.46 m | $727,454.31 |
| Operating Profit | -$31.33 m | -$49.75 m | -$27.39 m |
| Pre-Tax profit | -$32.38 m | -$49.34 m | -$26.87 m |
Shield Therapeutics PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group's main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment. |
| Latest Interim Date | 4 Sep 2024 |
| Latest Fiscal Year End Date | 30 Apr 2024 |
Shield Therapeutics PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2024-05-10 | Mr. Hans Peter Hasler | Non-Executive Director,Chairman |
| 2018-06-27 | Dr. Andrew John William Heath | Non-Executive Director,Chairman |
| 2020-06-18 | Mr. James Michael Karis | Non-Executive Director,Chairman |
| 2022-07-01 | Mr. Timothy William Watts | Executive Director |
| 2024-05-10 | Ms. Maria Fabiana Lacerca-Allen | Non-Executive Director |
| 2017-09-14 | Ms. Joanne Elizabeth Estell | Executive Director,Chief Financial Officer |
| 2024-07-24 | Mr. Gregory Paul Madison | Executive Director,Group Chief Executive Officer |
| 2024-05-10 | Mr. Peter Hermann William Llewellyn-Davies | Non-Executive Director |
| 2017-05-04 | Mr. Richard Crispin Morgan Jones | Executive Director,Chief Financial Officer and Company Secretary |
| 2020-04-22 | Mr. Carl Andrew Sterritt | Executive Director,Chief Executive Officer |
| 2024-05-10 | Dr. Christian Schweiger | Non-Executive Director |
| 2024-05-10 | Mr. Karl Anders Lundstrom | Executive Director,Chief Executive Officer (Interim) |
Shield Therapeutics PLC Contact Details
| Company Name | Shield Therapeutics PLC |
|---|---|
| Address | Northern Design Centre Studio 6, 3rd Floor, Baltic Business Quarter, Newcastle, NE8 3DF |
| Telephone | +44 1915118500 |
| Website | https://www.shieldtherapeutics.com |
Shield Therapeutics PLC Advisors
| Stockbroker | Peel Hunt LLP |
|---|---|
| Phone | +44 2074188900 |
| Remuneration Consultant | Deloitte LLP |
|---|---|
| Phone | +44 2079363000 |
| Fax | +44 2075831198 |
| Auditor | KPMG |
|---|---|
| Phone | (0191) 401 3700 |
| Fax | (0191) 401 3750 |
| Financial PR Adviser | Consilium Strategic Communications |
|---|---|
| Phone | +44 2037095700 |
| Solicitor | Stephenson Harwood |
|---|---|
| Phone | +44 2073294422 |
| Fax | +44 2073297100 |
| Stockbroker | Liberum Capital Limited |
|---|---|
| Phone | +44 2031002000 |
| Fax | +44 2031002299 |
| Registrar | Capita Asset Services |
|---|---|
| Phone | +44 8716640300 |
| Fax | +44 2086392342 |
| Nominated Adviser | Liberum Capital Limited |
|---|---|
| Phone | +44 2031002000 |
| Fax | +44 2031002299 |
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Dr. Martens PLC | 53.65 | 6.13 |
| Anglo American PLC | 2,254.50 | 6.22 |
| Antofagasta PLC | 1,934.50 | 6.00 |
| Prudential PLC | 668.40 | 4.67 |
| Rio Tinto PLC | 5,042.00 | 4.40 |
| Glencore PLC | 401.60 | 4.35 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Smiths Group PLC | 1,684.50 | -7.45 |
| Dunelm Group PLC | 1,167.00 | -5.51 |
| Barr (A.G.) PLC | 627.00 | -5.29 |
| Sthree PLC | 376.00 | -4.93 |
| Hunting PLC | 386.50 | -2.89 |
| Molten Ventures PLC | 398.68 | -2.64 |